Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Shares, par value CHF 0.08 per share
-
Shares outstanding
-
124,261,423
-
Total 13F shares
-
34,475,113
-
Share change
-
+599,788
-
Total reported value
-
$274,062,429
-
Put/Call ratio
-
74%
-
Price per share
-
$7.95
-
Number of holders
-
52
-
Value change
-
+$4,571,679
-
Number of buys
-
29
-
Number of sells
-
12
Institutional Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q2 2022
As of 30 Jun 2022,
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) was held by
52 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
34,475,113 shares.
The largest 10 holders included
FMR LLC, Redmile Group, LLC, JPMORGAN CHASE & CO, ALLIANCEBERNSTEIN L.P., PRICE T ROWE ASSOCIATES INC /MD/, EVENTIDE ASSET MANAGEMENT, LLC, GCM Grosvenor Holdings, LLC, PICTET ASSET MANAGEMENT SA, Vantage Consulting Group Inc, and Walleye Capital LLC.
This page lists
52
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.